trial

Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype

NCTId NCT01078870
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 75 (estimated)
Sponsored by National Taiwan University Hospital
Primary completion 2011-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
75 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2010-02
Primary completion
2011-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LexaproCymbalta

Sponsors

National Taiwan University HospitalLead Sponsor

Investigators

1
Liu Chih-Min, MDPrincipal Investigator

Sites

1 total
Taipei, Taiwan

Facts & assertions

4 sourced
Enrollment
75
Phase
PHASE4
Primary Completion Date
2011-01
Status
UNKNOWN
relationships
The graph out of here
drug
Lexapro
drug
Cymbalta
drug
lead_sponsor
National Taiwan University Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Liu Chih-Min, MD
person